The synthetic prostaglandin analog 9,11-azoprosta-5,13-dienoic acid (azo analog I) has been found to be a potent inhibitor of human platelet thromboxane synthetase by three independent analytical methods: electron-capture gas chromatography, radioisotopic thin-layer chromatography, and radioimmunoassay. In the presence of azo analog I, human platelet agegation induced by either the prostaglandin endoperoxide PGH2 or arachidonic acid was antagonized. The addition of azo analog I shifted the transformation of endoperoxides away from thromboxane synthesis and toward prostaglandin E2 synthesis. The specificity of azo analog I is demonstrated by its selective inhibition of the second wave of either ADP-or epinephrine-induced platelet aggregation. These data indicate that PGH2 must be converted to thromboxane A2 in order to induce human platelet aggregation. The isolation and structural characterization of the prostaglandin (PG) precursor molecules, the endoperoxides PGG2 and PGH2, by Hamberg, Samuelsson, and their coworkers (1, 2) initiated a new field of PG research. The endoperoxides were found-to have triphasic effects on blood pressure, to contract rabbit aorta, to increase airway resistance, and to induce human platelet aggregation (3). Prior to the isolation of the endoperoxides, Piper and Vane (4) had described the release of a rabbit-aorta-contracting substance (RCS) from guinea pig lung. The synthesis of RCS was inhibited by aspirin-like drugs that are known to inhibit PG biosynthesis (5). From these data it was suggested that RCS might be an endoperoxide or other PG precursor. However, studies performed with pure endoperoxide suggested that RCS had a considerably shorter half-life than PGH2 (30 sec versus 5 min) (6).
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Subsequent studies (7) have shown that, in platelets, PGH2 is converted to an unstable compound, with a bicyclic acetal ring structure, that induces human platelet aggregation and has a half-life of 30 sec. Because this compound and its stable metabolite lack the prostanoic acid skeleton and are formed in thrombocytes (platelets), they were named "thromboxanes (TX)." The unstable molecule was named thromboxane A2 (TXA2), and its hydrolysis product, thromboxane B2 (TXB2) (7) . TXA2 has been found to have all of the properties of RCS, and it has been suggested that RCS is a mixture of endoperoxides and TXA2 (7) . Fig. 1 outlines the synthesis of endoperoxides and TXs from arachidenic acid in platelets. We have reported that PGH2 (8) or TXA2 (9) can induce platelet aggregation and inhibit PGEI-stimulation of adenosine 3':5'-cyclic monophosphate (cAMP) accumulation in platelets. TXA2 was more potent than PGH2 on a molar basis, but it was not clear whether or not PGH2 had to be converted into TXA2 in order to inhibit cAMP accumulation or to induce aggregation (9), although Needleman et al. (10) have reported a dissociation between the generation of RCS (TXA2) and platelet aggregation.
Corey et al. (11) reported the synthesis of 9,11-azo-15-hydroxyprosta-5,13-dienoic acid, a powerful endoperoxide mimic that induces human platelet aggregation. In this report we will show that 9,11-azoprosta-5,13-dienoic acid (azo analog I) (which differs by removal of the 15S-hydroxyl group) is a potent inhibitor of TX synthetase and that, when TXA2 synthesis is blocked, platelet aggregation is also inhibited.
MATERIALS AND METHODS General
Human platelet-rich plasma was prepared by collecting 45 ml of whole blood into 5 ml of sterile 3.8% (wt/vol) sodium citrate (Upjohn) and centrifuging it for 10 min at 200 X g. Washed human platelets were prepared according to Miller et al. (12) , and platelet microsomes were prepared by the method of Needleman et al. (13) . Aggregation studies with both platelet-rich plasma and washed platelets were done on the Payton aggregation module according to Nishizawa et al. (14) and results are reported as percent transmission.
PGH2 was prepared biosynthetically according to Gorman et al. (15) , and TXB2 standard was prepared by total organic synthesis according to Nelson and Jackson (16) . TXB2 formation from PGH2 was quantitated by electron-capture gas chromatography by derivatization of TXB2 to a novel pentafluorobenzyloxime according to Fitzpatrick et al. (17) .
The conversion of PGH2 to TXB2 was also measured by quantitative radioisotopic thin-layer chromatography. The reaction medium contained 50 mM Tris-HCl (pH 8.0), 0.2 mg of platelet microsomal protein, and 10,uM PGH2 (1.5 X 105 cpm). The reaction mixture was incubated at 370 for 5 according to Fitzpatrick et al. (18) . Briefly, samples (0.1 ml) of platelets were removed from the incubation mixture at the specified time interval and mixed with 0.4 ml of phosphatebuffered saline containing flurbiprofen (20,ug/ml) followed by immediate freezing in liquid nitrogen. Samples were diluted 1:10, and 0.1-ml portions were used for assay.
[3H]TXB2 (0.1 ml = 104 cpm) was added to antiserum (0.1 ml) at a dilution (1:200 to 1:400) that bound 50% of the radiolabeled TX in the absence of competition by "cold" TXB2. Tubes were vortex mixed and then incubated for 1 hr at 250 and for 16-24 hr at 40. Antibody-bound and free TXB2 were separated with dextran-coated charcoal and the supernatant was assayed for radioactivity of [3H]TXB2. Data are presented as ng of TXB2 per ml of platelet suspension.
Synthesis of azo analog I. The synthetic pathway is outlined in Fig. 2 (i) silylation (20) (6 equivalents of t-butyldimethylsilyl chloride plus 12 equivalents of imidazole in dimethylformamide, 250, 20 hr), (ii) hydrolysis of the silyl ester (aqueous KOH), (iii) hydrogenolysis of the C-15 allylic oxygen function (7 equivalents of lithium plus 3 equivalents of neopentyl alcohol in methylamine, -300, 30 min), and (iv) silyl ether hydrolysis (dilute aqueous hydrochloric acid, tetrahydrofuran, 50°, 18 hr). The 15-deoxy-PGF2a synthesized in this manner was accompanied by substantial amounts (up to 20%) of the corresponding A14 isomer, from which it was readily separable chromatographically (acid-washed silica gel, elution with 30-40% ethyl acetate/hexane). After removal of the less polar A14 by-product, the 15-deoxy-PGF2a was identical chromatographically and spectrally to an authentic sample synthesized by an independent route.* After esterification (methyl iodide, diisopropylethylamine, acetonitrile, 250, 3 hr), inversion of the C-9 and C-11 hydroxyls of 15-deoxy-PGF2a methyl ester cupric acetate catalyst, 250, 30 min) to the desired 15-deoxy azo analog I in 40% overall yield from 9. After chromatographic purification (acid-washed silica gel, elution with 30% ethyl acetate/cyclohexane; RF, 0.18 in 30% ethyl acetate/hexane + 1% acetic acid), the purified azo analog I exhibited Vmax 3300 (OH), 1710 (CO2H), and 1495 cm-' (N=N) and A EtOH 341 m/u (e = 146); it gave nuclear magnetic resonance signals for the C-9 and C-li hydrogens at 5.15 and 4.95 ppm. This material is stable for at least 2 weeks at 50°(neat; oil).
RESULTS
The first indications that azo analog I might be a TX synthetase inhibitor are shown in Fig. 3 . PGH2 was a potent inducer of aggregation of human PRP, and this aggregation was antagonized by 5.6 uM azo analog I. The potent endoperoxide analog (15S)-hydroxy-9#,1 1#-(epoxymethano)prosta-SZ, 13E-dienoic acid (9-epoxy CEE) also induced platelet aggregation but this was not antagonized by azo analog I. This indicated to us that azo analog I was not inhibiting the PGH2-induced aggregation through an increase in cAMP, because an increase in cAMP also would have antagonized the 9-epoxy CEE-induced aggregation. Subsequent studies have shown that azo analog I does not increase platelet cAMP (unpublished data). Azo analog I was also found to inhibit selectively the second wave of platelet aggregation induced by either 0.8,uM ADP or 3.0MM epinephrine. The second wave of aggregation induced by these agents is also selectively inhibited by flurbiprofen, the prostaglandin cyclo-oxygenase inhibitor. However, our analysis of azo analog I showed it to have little if any cyclo-oxygenase inhibiting activity (unpublished data). The finding that collagen-induced aggregation was also inhibited by azo analog I supported our conclusion that it was a TX synthetase inhibitor. TXB2 is a hydrolysis product of TXA2 that can be isolated and quantitated. If azo analog I were TX synthetase inhibitor, it should inhibit TXB2 formation from arachidonic acid or PGH2.
Incubation of [1-'4C]PGH2 with platelet microsomes followed by extraction and thin-layer chromatography yielded the radiotrace shown in Fig. 4A . The primary radioactive product proved to be TXB2. Repeating this incubation with 1 qM azo analog I resulted in an almost complete inhibition of TXB2 synthesis (Fig. 4B) . Under these conditions, PGH2 is channeled away from TXB2, primarily to PGE2. As lower concentrations of azo analog I were used, the PGE2 peak diminished and the TXB2 peak reappeared.
In the second analytical study, washed human platelets were incubated with 2.8 ,uM PGH2 and allowed to aggregate. After 3 min, the reaction was stopped, and the resulting PGs were extracted, derivatized, and subjected to electron-capture gas chromatography. Fig. 5A shows both the aggregometer trace and the elution profile. Peak 1 corresponds to PGA2, peak 2 to PGB2, peak 3 to a mixture of PGE2 and PGD2, and the doublet peak 4 to the syn-and anti-isomers of TXB2. When the same procedure was repeated except that the platelets were preincubated for 2 min at 370 with 5.6 ,M azo analog I before the addition of PGH2, the PGH2-induced aggregation was inhibited and doublet peak 4 was absent (Fig. 5B) . Coincident with the disappearance of doublet peak 4, peak 3, which included PGE2 and PGD2, increased.
The third analytical technique used to measure TXB2 was radioimmunoassay. Fig. 6 shows human platelet aggregation in response to arachidonic acid at 500,ug/ml. We removed 100-,l aliquots from the aggregating platelets and analyzed them for TXB2 and PGE2 formation. The aggregation was very rapid and coincided well with the appearance of TXB2. In the presence of 2.8, 5.6, or 14.0,uM azo analog I, both the onset of aggregation and the appearance of TXB2 were delayed. This is again a strong correlation between the appearance of TXB2 and the initiation of platelet aggregation. Of particular interest was the observation that, as the concentration of azo analog I was increased and TXB2 synthesis was inhibited, the synthesis of PGE2 increased. A higher concentration of azo analog 1 (19.6 AM) was found to completely inhibit arachidonic acid-induced aggregation in this experiment (data not shown).
DISCUSSION
Azo analog I proved to be a potent inhibitor of platelet aggregation induced by PGH2, arachidonate, or collagen and of the second wave of ADP-or epinephrine-induced aggregation, without inhibiting 9-epoxy CEE-induced platelet aggregation or the first wave of ADP-or epinephrine-induced aggregation. Azo analog I does not work by increasing cAMP, because increased cAMP levels cannot selectively inhibit the second wave of aggregation due to ADP or.epinephrine. In the presence of agents that increase cAMP, there is no demonstrable aggregation with either ADP or epinephrine. The mechanism of action also could not be due to an inhibition of the PG cyclo-oxygenase. Inhibitors of the cyclo-oxygenase can inhibit second-wave aggregation selectively, but do not inhibit a PGH2-induced aggregation (1) . These data suggested that azo analog I was a TX synthetase inhibitor. Direct measurement of TXB2 formation in the presence of azo analog I supported the aggregation data. Three independent analytical techniques all showed azo analog I to be a TX synthetase inhibitor. These methods also indicated that, when the TX synthetase was inhibited by azo analog I, PGH2 was channeled primarily toward PGE2. These data also support our earlier finding that azo analog I is not a PG cyclo-oxygenase inhibitor, because large amounts of PGE2 are produced during a TXA2 synthetase block.
The measurements of TXB2 production during arachidonic The discovery of a TXA2 synthetase inhibitor is particularly exciting in light of the recent discovery and characterization of prostacyclin (26, 27) . Prostacyclin, which is derived from PGH2, is a potent inhibitor of platelet aggregation and stimulator of platelet adenylate cyclase (28, 29) . Platelets apparently do not synthesize prostacyclin, but the PGH2 formed by platelets can be converted to prostacyclin by vessel walls (26) . An (26) .
Inhibitors of the TX synthetase should also be valuable as research tools, because they will permit the dissection of PGH2-mediated effects from TXA2-controlled processes without inhibiting the synthesis of other products of arachidonic acid metabolism.
